Comparative Pharmacology
Head-to-head clinical analysis: COR OTICIN versus CORDRAN SP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COR OTICIN versus CORDRAN SP.
COR-OTICIN vs CORDRAN SP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
Topical corticosteroid that induces phospholipase A2 inhibitory proteins (lipocortins), inhibiting arachidonic acid release and subsequent prostaglandin and leukotriene synthesis, thereby mediating anti-inflammatory, antipruritic, and vasoconstrictive effects.
1-2 drops in each affected ear twice daily for 7 days.
Apply a thin film to the affected area 1 to 2 times daily. Use the smallest amount for adequate therapy. Do not use for more than 2 weeks per course of treatment.
None Documented
None Documented
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
Terminal half-life approximately 48 hours; prolonged with hepatic impairment.
Renal (60-80% unchanged), fecal/biliary (5-10%)
Primarily renal as inactive metabolites; <5% unchanged. Minimal biliary/fecal elimination.
Category C
Category C
Topical Corticosteroid + Antibiotic
Topical Corticosteroid